Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals develops, manufactures, and sells medicines for various diseases worldwide. Products include EYLEA for eye conditions, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for hypercholesterolemia and cardiovascular disease, REGEN-COV for COVID-19, Kevzara for rheumatoid arthritis, Inmazeb for ebolavirus infection, ARCALYST for cryopyrin-associated periodic syndromes, and ZALTRAP for metastatic colorectal cancer.
Overview
Strengths
- Creates economic value: ROIC of 14.7% against a cost of capital (WACC) of 5.7%, a spread of 9.0 percentage points.
- Pricing power: gross margin has held between 85% and 87% over the last 6 years (latest 85.4%).
- Consistent growth: revenue has compounded at 11.0% a year over 5 years, rising in 4 of them.
- Scale advantage: ranks #2 by enterprise value ($95 billion) among the 129 Biotechnology companies we cover.
- EBITDA margin of 36.6% beats 80% of its 128 Biotechnology peers (median 0.0%).
- Net cash balance sheet: cash exceeds total debt.
Weaknesses
- Our discounted cash flow target price (519.68 USD) is 42% below the current price.
- More expensive than its own history: EV/EBITDA 19.0x vs. a historical average of 12.8x.
Key Financial Data